Advertisements Of Health Products Promoted On TV

New Delhi : Minister of Information and Broadcasting; and Minister of Youth Affairs and sports Anurag Singh Thakur replied on 21.3.2023 in a Starred question No. 288 of Sanjay Sadashivrao Mandlik and Dhairyasheel Sambhajirao Mane in Lok Sabha that “Advertising Standards Council of India (ASCI) is a nonstatutory, non-Governmental, voluntary self-regulation organization of the advertising industry. Its report, guidelines etc. are available on its website i.e. https://ascionline.in/.

All advertisements telecast on private satellite TV channels are required to adhere to the Advertising Code prescribed under the Cable Television Networks (Regulation) Act, 1995 and rules framed thereunder.

For print media the Press Council of India (PCI), a statutory body established under the Press Council Act, 1978, has issued norms relating to advertisements in its ‘Norms for Journalistic Conduct’. PCI has a complaint mechanism for redressing complaints.

A Central Consumer Protection Authority (CCPA) has been established under the provisions of Consumer Protection Act, 2019 w.e.f. 24.07.2020 which inter-alia looks into misleading advertisements either suo-moto or on complaints or on directions from the Central Government. CCPA has notified ‘Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022’ on 9th June, 2022.”

Earlier the minister replied in Unstarred Question No. 1844 answered on 22.12.2022 that “Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder provides for prohibition of misleading advertisements and exaggerated claims of drugs and medicinal substances (including AYUSH medicines). The Central Government has notified Rule 170 in the Drugs & Cosmetics Rules, 1945 on 24th December, 2018 specifically for controlling inappropriate advertisements of Ayurvedic, Siddha and Unani medicines. An institutional mechanism at the central and state levels have been set up for enforcement and taking action in case of violation.”

Ramdev-promoted FMCG company Patanjali Ayurved’s advertising promotional expenses for the fiscal ended 31st March 2021 has increased 3.26% to Rs 294.09 crore from Rs 284.79 crore in the previous fiscal, according to financial data accessed by business intelligence platform.
  • Related Posts

    Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

    CBI has said the Delhi Police inspector accepted the first instalment of a larger payoff from the key accused in the Rs 5,000-crore counterfeit medicine racket. The Central Bureau of…

    No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

    The Maharashtra government on Wednesday informed the Bombay High Court that it will not carry out raids and a confiscation drive against ayurvedic products over allegedly misleading ‘indication’ labels until…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

    Bribe of Rs 3 crore: Delhi Police inspector held, senior public servant under CBI scanner

    No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

    No raids till further orders: Maharashtra tells Bombay HC in Patanjali labelling case

    Crackdown on Illegal Sale of Mephentermine Sulphate Injections in Warangal Gyms

    Crackdown on Illegal Sale of Mephentermine Sulphate Injections in Warangal Gyms

    Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

    Ajanta Pharma Promoter Sell 3% Stake Worth ₹1,024 Crore; Shares Trade Higher

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk

    ICMR-NIN study links micronutrient deficiencies to higher dementia risk